MannKind Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference
March 19 2018 - 8:00AM
MannKind Corporation (Nasdaq:MNKD) focused on the
development and commercialization of inhaled therapeutic products
for patients with diseases such as diabetes and pulmonary arterial
hypertension, today announced it will be featured as a presenting
company at the H.C. Wainwright Annual Global Life Sciences
Conference at 1:45 PM (CET) on April 9, 2018. The conference
is being held at the Le Meridien Beach Plaza Hotel in Monte
Carlo, Monaco.
Michael Castagna, Chief Executive Officer, of
MannKind Corporation, will provide an overview of the Company's
business during the live presentation and will participate in
one-on-one meetings with investors who are registered to attend the
conference.
If you are an institutional investor, and would
like to attend the Company’s presentation, please click on the
following link (www.hcwevents.com ) to register for the
conference. Once your registration is confirmed, you will be
prompted to log into the conference website to request a one-on-one
meeting with the Company.
The presentation will be webcast live. To
access the webcast, please visit www.hcwevents.com.
Interested parties can also access a link to the live webcast of
the presentation from the News & Events section of the
Company's website at http://www.mannkindcorp.com. The webcast
replay will remain available for 90 days following the live
presentation.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) inhalation powder, the Company's first
FDA-approved product and the only inhaled rapid-acting mealtime
insulin in the United States, where it is available by prescription
from pharmacies nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs field
sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Words such
as "believes", "anticipates", "plans", "expects", "intend", "will",
"goal", "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon the MannKind's current
expectations. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, the risks detailed in MannKind's
filings with the Securities and Exchange Commission, including the
Annual Report on Form 10-K for the year ended December 31, 2017 and
subsequent periodic reports on Form 10-Q and current reports on
Form 8-K. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. All forward-looking
statements are qualified in their
entirety by this cautionary
statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
MannKind Contact:Rose
AlinayaSVP, Investor Relations818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024